Clinical trials: FDG-PET
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or…
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer
- Trial name
- NCT00559377
- Testing
- 18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Cystic Fibrosis
FDG-PET Imaging in Young Cystic Fibrosis Patients
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.
- Trial name
- NCT00846053
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Nonneoplastic Condition
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00822120
- Testing
- bleomycin sulfate, filgrastim, ABVD regimen
- Where
- 423 sites in United States
- Volunteers
- 371 people
- Sponsor
- SWOG Cancer Research Network
Cervical Cancer, Uterine Cancer
Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
18F Fluciclovine is a recently FDA- approved radiopharmaceutical for prostate cancer biochemical recurrence, which is only minimally eliminated by the kidneys and therefore the image interpretation is not affected by nonspecific…
- Trial name
- NCT03423082
- Testing
- 18F fluciclovine, 18F fluciclovine PET
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Nghi Nguyen
Cervix Cancer, Endometrial Cancer
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor.
- Trial name
- NCT04514692
- Testing
- GCSF
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Hypermetabolic Lymphadenopathy Mediastinum Lower, Posterior and Middle, Detected by PET-CT With 18F-FDG (PET)
Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy
Impact of screening nodes mediastinal by PET, at different times of the management of cancer disease, remain unclear. Benefits of combined PET and puncture with echoendoscopy for the diagnosis subsequent therapeutic management…
- Trial name
- APOGEE (NCT01892501)
- Testing
- Guided punction of mediastinal lymphadenopathy by echoendoscopy, PET scan
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Institut Bergonié
Brain Cancer
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing.
- Trial name
- NCT01604512
- Testing
- MRI perfusion and PET/CT scans
- Where
- 6 sites in United States
- Volunteers
- 148 people
- Sponsor
- Memorial Sloan Kettering Cancer Center